Concurrent therapy with other Investigational Products.
Patient has history of allergy to any oily drug products
Treatment with any investigational products within  days before the first dose of protocol-indicated treatment
Treatment with any investigational products within  days prior to study registration
Treatment with any investigational products within  weeks before administration of the first dose of the study drugs.
Treatment with any investigational products within  days before randomization.
Treatment with any investigational products within  days before the first dose of study drug
Treatment with any investigational products within  weeks before the first dose of study drug.
Known prior or suspected hypersensitivity to investigational products
Treatment with any investigational products within  days before the first dose of any study drug
Previous treatment with venetoclax and/or current participation in any other research study with investigational products.
Concurrent therapy with other investigational products
Treatment with any investigational products within  days before the first dose of any study drug
Currently using aluminum-containing antacid products
Confirmed availability of production capacities for the patient's ACTolog products.
Previous treatment with investigational gene or cell therapy medicine products
Treatment with any investigational products within  days before the first dose of study drug
Treatment with any investigational products within  weeks before the first dose of study drug
Consumption or use of any Noni or Noni-containing products
User of herbal products
Treatment with any investigational products within  weeks before the first dose of study drug
History of allergy or untoward reaction to yeast-based products (any hypersensitivity to yeast-based products will be excluded)
Within the month immediately preceding the screening visit, use of any form of tobacco products other than cigarettes on  or more days within a week if the individual refuses to refrain from such tobacco use during the course of the study
History of hypersensitivity reactions to products containing irinotecan (irinotecan), topotecan or other topoisomerase inhibitors, gadolinium contrast agents or lipid products
Previous treatment with any substrate of CYPB enzyme <  days prior to initiation of investigational products
Treatment with any investigational products within  weeks before the first dose of any study drug
Patients taking any clay products
Concurrent use of tobacco products (other than cigarettes) or nicotine products.
Treatment with any investigational products within  days prior to study registration
Treatment with other investigational products within the last  months prior to entry into this study
Individuals who are willing to not start any new products OTC or prescription treatments for Paronychia and discontinue any treatment the investigator feels may interfere with the evaluation of the test products
Treatment with any anti leukemic/anti MDS therapies (eg, lenalidomide, cytarabine, anthracyclines, purine analogs) or with any investigational products within  days before the first dose of any study drug.
Known hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study products
Not be allergic to tomatoes or tomato products
Any major surgery =<  days prior to the initiation of investigational products
Treatment with any investigational products within  days before the first dose of the study drug regimen.
Received radiation therapy =<  days prior to initiation of investigational products
Known prior or suspected hypersensitivity to investigational products.
Treatment with any investigational products within  weeks before the first dose of any study drug
Treatment with any investigational products within  days before the first dose of study drug
Treatment with any investigational products within  days before the first dose of the study drug regimen
Patients who have used tobacco or nicotine products or medications within the last three months given their significant effect on erlotinib drug levels
Treatment with chemotherapy, radiotherapy, surgery, blood products, or an investigational agent within  weeks of trial enrolment
Therapy with herbal products known to effect PSA, or estrogen within  days prior to the start of study medication
Hypersensitivity to tea products or any of the inactive ingredients found in the drug product capsules
At least  weeks since the last chemotherapy, radiation therapy, immunotherapy or any investigational products
Treatment with any anticancer therapy or any investigational products within  weeks before the first dose of study drug.
Treatment with any systemic antineoplastic therapy or investigational products within  days before the first dose of study treatment.
Treatment with any investigational products  days prior to treatment
PART I: Participants who smoke tobacco products will not be allowed to participate
PART II: Those who smoke tobacco products will not be allowed to participate
Treatment with any investigational products
Exposure to more than  investigational medicinal products within  months prior to the first dose of study treatment
Subjects must not be currently using other tobacco or nicotine products.
Investigational products or therapy other than ASP
Therapy with any investigational products within  days before the first dose of study drug
Regular use of tobacco products other than cigarettes
Willingness to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment
Extensive history of using smokeless tobacco products or marijuana defined as daily use >=  years
Use of any estrogen containing medications, products, or preparations
Abstention from meat and other animal products
Willing to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment
Willing to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment
Current use of tobacco/tobacco-containing products;
Exclusive use of tobacco products other than cigarettes, such as (but not limited to) cigars, chew, snuff, pipe or electronic (e)-cigarettes (cigs).
Not be allergic to tomato or tomato products
Used other tobacco products (including e-cigarettes) more than  days in the past month
Willing to abstain from cannabis and other tobacco products during study procedures
Within the month immediately preceding the screening visit, use of any form of tobacco products other than cigarettes, little cigars or cigarillos on  or more days within a week if the individual refuses to refrain from such tobacco use during the course of the study
Smoker or uses smokeless tobacco products
Use of tobacco products other than cigarettes in past  days
Within the month immediately preceding the screening visit, use of any form of tobacco products other than cigarettes, little cigars or cigarillos on  or more days within a week if the individual refuses to refrain from such tobacco use during the course of the study
STUDY I: Former dual users who have quit both products
Allergic to fish products
Use of tobacco products other than cigarettes in past  days
Currently using nicotine replacement or other tobacco cessation products or intentionally abstaining from nicotine-containing products
Hypersensitivity to potassium iodide or Lugols products
Hypersensitivity to iodide products
No known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the dental/medical professional monitoring the study
History of significant adverse effects following use of oral hygiene products such as toothpastes and mouth rinses; allergy to personal care/consumer products or their ingredients
Received other investigational products or therapy in the  days prior to study drug administration.
Use of tobacco- or nicotine-containing products in excess of the equivalent of  cigarettes per day
Use in the past  days of tobacco or nicotine products including e-cigarettes, other than regular cigarettes
Current use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes) or use of these products within  months of study registration
Other tobacco use (e.g., combustible products, vapors, etc.) within the last  months
Regular use (e.g., greater than weekly) of tobacco products (including e-cigarettes) other than cigarettes
Use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes)
Subject has provided written informed consent to participate in the study\n             (adolescents under the age of  will be excluded because this project involves\n             continued use of tobacco products and new tobacco products);
Pregnant or breastfeeding (due to toxic effects from tobacco products).